Last reviewed · How we verify
multi-epitope melanoma peptide vaccine
multi-epitope melanoma peptide vaccine is a Biologic drug developed by Craig L Slingluff, Jr. It is currently in Phase 2 development. Also known as: 12 Melanoma peptides from melanocyte differentiation protein (MDP) and cancer testis antigen (CTA),, 12 melanoma peptides restricted by class I MHC molecules,restricted by HLA-A1, A2, or A3 molecules, MULTI-EP MP VAC.
At a glance
| Generic name | multi-epitope melanoma peptide vaccine |
|---|---|
| Also known as | 12 Melanoma peptides from melanocyte differentiation protein (MDP) and cancer testis antigen (CTA),, 12 melanoma peptides restricted by class I MHC molecules,restricted by HLA-A1, A2, or A3 molecules, MULTI-EP MP VAC |
| Sponsor | Craig L Slingluff, Jr |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma (PHASE2)
- Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma (PHASE1, PHASE2)
- Vaccine Therapy With or Without Imiquimod in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma (PHASE1)
- Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery (PHASE1)
- Vaccine Therapy in Treating Patients With Advanced Melanoma (PHASE1)
- Vaccine Therapy With or Without Sargramostim in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma (PHASE2)
- Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery (PHASE2)
- Vaccine Therapy in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- multi-epitope melanoma peptide vaccine CI brief — competitive landscape report
- multi-epitope melanoma peptide vaccine updates RSS · CI watch RSS
- Craig L Slingluff, Jr portfolio CI
Frequently asked questions about multi-epitope melanoma peptide vaccine
What is multi-epitope melanoma peptide vaccine?
multi-epitope melanoma peptide vaccine is a Biologic drug developed by Craig L Slingluff, Jr.
Who makes multi-epitope melanoma peptide vaccine?
multi-epitope melanoma peptide vaccine is developed by Craig L Slingluff, Jr (see full Craig L Slingluff, Jr pipeline at /company/craig-l-slingluff-jr).
Is multi-epitope melanoma peptide vaccine also known as anything else?
multi-epitope melanoma peptide vaccine is also known as 12 Melanoma peptides from melanocyte differentiation protein (MDP) and cancer testis antigen (CTA),, 12 melanoma peptides restricted by class I MHC molecules,restricted by HLA-A1, A2, or A3 molecules, MULTI-EP MP VAC.
What development phase is multi-epitope melanoma peptide vaccine in?
multi-epitope melanoma peptide vaccine is in Phase 2.
Related
- Manufacturer: Craig L Slingluff, Jr — full pipeline
- Also known as: 12 Melanoma peptides from melanocyte differentiation protein (MDP) and cancer testis antigen (CTA),, 12 melanoma peptides restricted by class I MHC molecules,restricted by HLA-A1, A2, or A3 molecules, MULTI-EP MP VAC
- Compare: multi-epitope melanoma peptide vaccine vs similar drugs
- Pricing: multi-epitope melanoma peptide vaccine cost, discount & access